BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.…
BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
BlossomHill Therapeutics (NASDAQ: BLSM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 14.51 USD on 20 November 2026. Its 52-week range is 11.02 USD to 27.99 USD: the price is 48.2% below the high and 31.7% above the low.
Its market capitalisation is 461.20M USD.
BlossomHill Therapeutics reports return on equity of 46.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 201.81M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 35.40 USD is 144.0% above the current price. The next earnings report is expected on 8 March 2027.